DEVIATION INVESTIGATIONS A Proper Objective Perspective

/ 21 []
Download Presentation
(1381) |   (0) |   (0)
Views: 388 | Added:
Rate Presentation: 0 0
DEVIATION INVESTIGATIONS A Proper Objective Perspective. FDA USP Conference Irvine, CA December 5, 2008. Investigations. Deviations (All departments) Out-of-Specification (QC Lab) Out-of-Trend (QC Lab) Raw Materials Components Containers/Closures API Finished Drug Product. Deviations.
DEVIATION INVESTIGATIONS A Proper Objective Perspective

An Image/Link below is provided (as is) to

Download Policy: Content on the Website is provided to you AS IS for your information and personal use only and may not be sold or licensed nor shared on other sites. SlideServe reserves the right to change this policy at anytime. While downloading, If for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Deviation investigations a proper objective perspective l.jpgSlide 1

DEVIATION INVESTIGATIONS A Proper Objective Perspective

FDA USP Conference

Irvine, CA

December 5, 2008

Investigations l.jpgSlide 2


  • Deviations (All departments)

  • Out-of-Specification (QC Lab)

  • Out-of-Trend (QC Lab)

    • Raw Materials

    • Components

    • Containers/Closures

    • API

    • Finished Drug Product

Deviations l.jpgSlide 3


  • Associated with limits vs. specifications

  • GMP mistakes or errors

    • Reprocessing or Rework

    • Unapproved changes

    • Performing an activity without proper training

    • Outside of operating parameters or in-process control limits

    • Failure to follow written SOPs or approved batch record instructions

Deviations4 l.jpgSlide 4


  • GMP mistakes or errors

    • Good documentation errors – missing entries, unexplained entries, improper corrections or edits to official records

    • Environmental Monitoring over alert or action limit excursions

    • Out of calibration

    • Unplanned preventive maintenance or repairs to ‘qualified’ equipment or systems

Deviation investigations l.jpgSlide 5

Deviation Investigations

  • Root Cause(s) – Thorough Investigations

    • What vs. Why or How

      • The 20 : 80 (what : why/how) Rule

  • Corrective Actions

    • Batch release dependent

  • Preventive Actions

    • Batch release independent

Deviation investigations6 l.jpgSlide 6

Deviation Investigations

  • Deviation investigations must not be biased from the start

    • From an FDA or cGMP perspective, the purpose of conducting a deviation investigation is not to “release the batch.”

    • The true purpose of a deviation investigation is to

      • determine the root cause for the “deviation”\

      • implement appropriate and meaningful corrective actions, and

      • evaluate the implicated system (e.g., the training program) once a pattern of repeating deviations is noted.

Deviations investigations vs batch release product impact assessments l.jpgSlide 7

Deviations Investigations vs. Batch Release (Product Impact Assessments)

Batch release should be considered a separate and distinct QA function and activity!

Product Impact Assessments should be done “collectively” (summation of all deviations) after an appropriate deviation investigation has been completed.

All deviations must then be collectively evaluated at the time of final batch release.

Deviations root cause s l.jpgSlide 8

DeviationsRoot Cause(s)

  • Documenting all attempts to identify, determine, confirm, or rule out potential root cause(s)

    • Why and how did it occur

  • Detailed descriptions (what, where, when, and who) of the deviation vs. root cause investigation or assessments

  • Definitive or Potential Root Cause(s)

Root causes l.jpgSlide 9

Root Causes

Definitive vs. Potential Root Causes


Corrective actions l.jpgSlide 10

Corrective Actions

  • Short term, immediate actions taken to “correct” or address the potential root cause(s) for each reported deviation

  • Actions designed to eliminate or minimize the potential for recurrence of the deviation

  • Must be initiated (accountability in a formal quality system) or completed prior to closing out of the investigation

  • Corrective actions should be tracked and trended in a quality system

Corrective actions11 l.jpgSlide 11

Corrective Actions

General FDA 483 Observation

Corrective actions do not ‘match’ or support definitive or potential root causes.

Deviations preventive actions l.jpgSlide 12

DeviationsPreventive Actions

  • Longer term actions designed to determine the effectiveness of corrective actions

  • Actions designed to ensure the “prevention” or recurrence of deviations

  • Preventive actions do not have to be initiated or completed prior to closing the investigation

  • Preventive actions should be tracked, monitored for completion, and trended in a quality system

Preventive actions l.jpgSlide 13

Preventive Actions

Preventive actions must focus on ‘system’ evaluations and ‘system’ level continuous improvement.

Quality system improvement is more important to FDA than corrective actions (band-aid fixes necessary to just release a batch).

Deviations fda s chronologic expectations l.jpgSlide 14

DeviationsFDA’s Chronologic Expectations

  • Deviation reported in real time

    • Timely notification of QA (within 24 hours)

  • Thorough root cause investigation

  • Timely investigation (within 30 days)

  • Corrective actions proposed and initiated or completed

  • Investigation closed

  • Implicated batch(es) released or rejected

  • Preventive actions initiated and closed

Planned deviations l.jpgSlide 15

Planned Deviations

  • Planned deviations should be handled through the QA approved change control procedures.

  • All changes should be evaluated for product impact, significance

    • The need for requalification or revalidation

    • Changes ultimately approved or rejected by QA.

  • QA should insist that planned deviations not be used; all deviations should be unintentional, unplanned, or unexpected.

  • Shutdown or validation protocols can also be used in lieu of planned deviations.

Deviation vs out of specification l.jpgSlide 16

Deviation vs. Out of Specification

  • Preliminary investigation

    • Purpose: Investigate to determine if the initial OOS test result is valid or invalid based on a review of the bench; do not discard sample preparation, pipettes, etc.

      • Analyst error

        • Sample preparation error

      • Instrument error

      • Reference standard

      • Calculation error

      • Failure to follow test method

Deviation vs out of specification17 l.jpgSlide 17

Deviation vs. Out of Specification

  • Once confirmed, invalid OOS test results should be converted to deviation investigations

  • Confirmed valid OOS test results should be investigated through the OOS procedure

    • Link to the failure investigation procedure for rejected materials, API, and/or finished product

Deviation management business perspective l.jpgSlide 18

Deviation ManagementBusiness Perspective

  • Measures of efficiency and productivity

    • Qualified suppliers

    • Higher yields

    • Process Optimization

  • Routine global senior management visibility

    • Competitive business strategic plans

  • QA quality systems evaluation

    • Regulatory insurance policy (CGMPs)

  • Mission or Vision Statements

    • “Do it right the first time”

    • “Quality First”

Final thoughts l.jpgSlide 19

Final Thoughts

  • Deviation investigations are not an unusual or foreign concept to industry or in our normal outside of work life

  • Workers compensation or injury at work

    • Consider steps taken with respect to EHS (safety or injury related) investigations, corrective action, and preventive action program.

    • Corrective actions are designed to target root cause(s).

    • Preventive actions are designed to ensure corrective actions are effective in avoiding work related injuries through appropriate ‘system’ level improvements.

Contact information l.jpgSlide 20

Contact Information

CDR Jeffrey T. Yuen, MPH, MBA

President – Principal Consultant

Jeff Yuen and Associates

P.O. Box 6026

Orange, CA 92863-6026

Phone: 714 282-1014

E-Fax: 240 597-8351


Reproduction or copies l.jpgSlide 21

Reproduction or Copies

Further reproduction, copies, or use of this presentation without explicit permission from Jeff Yuen and Associates is strictly prohibited.

November 13, 2003

Copyright © 2015 SlideServe. All rights reserved | Powered By DigitalOfficePro